Skip to main content

Fangzhou Showcases “AI+H2H” Chronic Disease Service Innovations at the National Intelligent Medicine Conference

Written by Customer Service on . Posted in Public Companies.

WUHAN, China, May 13, 2026 (GLOBE NEWSWIRE) — Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI‑driven Internet healthcare solutions, participated in the 2026 National Medical Industry Academic and Industry Integration Conference, held from May 6 to 9 in Wuhan. At the health management sub‑forum, Fangzhou presented its innovative “AI+Chronic Disease Service” solutions, addressing some of the most pressing challenges in chronic disease care.

AI+H2H Ecosystem Underpins Full‑Cycle Chronic Disease Care

In response to persistent challenges facing the healthcare industry, such as physicians’ time constraints, limited patient awareness of chronic disease risks, and poor medication adherence, Fangzhou emphasized the importance of integrated care that connects the hospital and the home. Drawing on a network of 251,000 registered doctors and a robust technology platform, the Company’s AI+H2H (Hospital‑to‑Home) ecosystem supports a full‑cycle approach to chronic disease management. Intelligent tools such as AI Health Assistants and AI Doctor Assistants streamline post‑clinic follow‑up, improve access to services, and extend care to more patients.

A Fangzhou executive commented at the sub‑forum: “Chronic disease management must bridge the gap between hospital and home by becoming part of patients’ everyday lives. Our AI+H2H approach helps deliver long‑term care that is coordinated, consistent, and personalized for every patient.”

Personalized Follow‑Up Delivers Tangible Outcomes

Chronic disease management requires long‑term engagement. Fangzhou centers its approach on structured follow‑ups, evolving from one‑off consultations to continuous care over the full course of a patient’s condition.

AI‑powered tools further improve efficiency. Patient feedback and assessment data are aggregated and reviewed to generate health reports for physicians, significantly reducing the administrative burden without sacrificing quality of care. Long‑term members also gain access to tailored health plans, dynamic monitoring, early‑warning alerts and individualized medication guidance, ensuring truly comprehensive, ongoing support.

Strengthening its Role as a Trusted Long‑Term Health Partner

In line with trends in intelligent healthcare and collaboration between industry and academia, Fangzhou continues to refine its AI+Chronic Disease Care ecosystem, broadening its service capabilities and enhancing the patient experience. The Company aims to be a trusted long‑term health partner, using technology to deliver accessible, high‑quality chronic disease management and to set a benchmark for sustainable innovation in healthcare.

About Fangzhou Inc.

Fangzhou Inc. (HKEX: 06086) is China’s leading online chronic disease management platform, serving 56.4 million registered users and 251,000 physicians (as of December 31, 2025). The Company specializes in delivering tailored medical care and AI‑enabled precision medicine solutions. For more information, visit https://investors.jianke.com.

Media Contact

For further inquiries or interview requests, please contact:

Xingwei Zhao
Director of Public Relations
Email: pr@jianke.com

Disclaimer: This press release contains forward‑looking statements. Actual results may differ materially from those anticipated due to various factors. Readers are cautioned not to place undue reliance on these statements.

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.